Thomas Prébet - Concepedia

Author

Thomas Prébet

Also Known As

Prébet, Thomas, Sarah Bertoli, T Prebet, T Prébet, T. Prebet, T. Prébet, THOMAS PREBET, Thomas Prebet, Thomas Prébet, Thomas Prébet

343

Publications

8.9K

Citations

H-Index

Concepts

All Affiliations

Institut Paoli-Calmettes Inserm Yale University Hôpital Saint-Louis Aix-Marseille Université

About

Thomas Prébet is an author at Institut Paoli-Calmettes specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	49	3.6K
2	Health Sciences	17	21	1.9K
3	Engineering	2	2	598
4	Public Health	1	1	33
5	Biostatistics	1	1	121

Thomas Prébet

Publications

7.3K

Citations

H-Index

Page 1

	Year	Citations
Mutations of polycomb‐associated gene <i>ASXL1</i> in myelodysplastic syndromes and chronic myelomonocytic leukaemia Véronique Gelsi‐Boyer, Virginie Trouplin, José Adélaı̈de, British Journal of Haematology EngineeringMixed-phenotype Acute LeukemiaGeneticsPathologyEpigenetics	2009	555
Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure Thomas Prébet, Steven D. Gore, Benjamin Esterni, Journal of Clinical Oncology	2011	475
Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy Ruxanda Moschoi, Véronique Imbert, Marielle Nebout, Blood	2016	438
Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology Martin S. Tallman, Eunice S. Wang, Jessica K. Altman, Journal of the National Comprehensive Cancer Network Hematological MalignancyHealth SciencesMedicineAcute Myeloid LeukemiaMixed-phenotype Acute Leukemia	2019	418
NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021 Daniel A. Pollyea, Dale L. Bixby, Alexander E. Perl, Journal of the National Comprehensive Cancer Network Hematological MalignancyTranslational MedicineOncologyMixed-phenotype Acute LeukemiaAcute Myeloid Leukemia	2021	314
A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission Norbert Vey, Jean Bourhis, Nicolas Boissel, Blood	2012	268
Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905 Thomas Prébet, Zhuoxin Sun, María E. Figueroa, Journal of Clinical Oncology	2014	244
Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes Frédérik Damm, Olivier Kosmider, Véronique Gelsi‐Boyer, Blood	2012	230
BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders Frédérik Damm, Virginie Chesnais, Yasunobu Nagata, Blood	2013	215
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial Uwe Platzbecker, Matteo Giovanni Della Porta, Valeria Santini, The Lancet Hematological MalignancyThrombosisInterim AnalysisBone Marrow FailurePhase 3	2023	154

Page 1